Health Technology Astellas Pharma, Inc. Business Summary
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Financial Highlights
Mar 2021
JPY USD Revenue 1,249.52B 11,781.61M Gross Profit 979,702M 9,237.46M Operating income 250,897M 2,365.67M Income before tax 144,846M 1,365.73M Net income 120,589M 1,137.01M EBITDA 323,549M 3,050.69M Diluted EPS 64.89 0.61 Dividends Per Share 42 0.39 Total Assets 2,273.62B 20,575.81M Total liabilities 887,514M 8,031.80M Total equity 1,386.11B 12,544.02M Operating cash flow 307,880M 2,902.95M Currency in JPY Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
1,311.66B
1,300.31B
1,306.34B
1,300.84B
1,249.52B
Gross Profit
955,325M
970,228M
979,086M
1,002.94B
979,702M
Operating income
276,419M
271,241M
280,141M
279,419M
250,897M
Income before tax
281,769M
218,113M
248,967M
247,010M
144,846M
Net income
218,701M
164,679M
222,265M
195,411M
120,589M
EBITDA
340,210M
336,104M
343,599M
345,815M
323,549M
Diluted EPS
103.55
81.02
114.94
104.07
64.89
Dividends Per Share
34
36
38
40
42
Total Assets
1,814.07B
1,858.20B
1,897.64B
2,315.16B
2,273.62B
Total liabilities
540,614M
583,608M
639,252M
1,026.00B
887,514M
Total equity
1,271.81B
1,268.28B
1,258.39B
1,289.16B
1,386.11B
Operating cash flow
237,230M
314,463M
261,428M
224,060M
307,880M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
12,112.80M
11,732.27M
11,780.07M
11,964.43M
11,781.61M
Gross Profit
8,822.11M
8,754.00M
8,828.97M
9,224.49M
9,237.46M
Operating income
2,552.63M
2,447.30M
2,526.19M
2,569.94M
2,365.67M
Income before tax
2,602.04M
1,967.95M
2,245.07M
2,271.86M
1,365.73M
Net income
2,019.63M
1,485.83M
2,004.28M
1,797.28M
1,137.01M
EBITDA
3,141.72M
3,032.54M
3,098.42M
3,180.61M
3,050.69M
Diluted EPS
0.95
0.73
1.03
0.95
0.61
Dividends Per Share
0.31
0.32
0.34
0.36
0.39
Total Assets
16,279.92M
17,472.54M
17,144.58M
21,445.68M
20,575.81M
Total liabilities
4,851.60M
5,487.61M
5,775.41M
9,503.95M
8,031.80M
Total equity
11,413.53M
11,925.61M
11,369.16M
11,941.71M
12,544.02M
Operating cash flow
2,190.74M
2,837.28M
2,357.44M
2,060.78M
2,902.95M
Valuation Measures
Mar 2021
PER 26.21 ROA 5.25% ROE 9.01% Operating margin 20.07% Profit margin 9.65%
Key executives
President, CEO & Representative Director:
Kenji Yasukawa
CFO, Representative Director & Vice President:
Naoki Okamura
Chief Scientific Officer:
Yoshitsugu Shitaka
Head-Business Administration & Compliance:
Fumiaki Sakurai
Senior VP-Product & Portfolio Strategy:
Claudia Mitchell Shareholders
Nomura Asset Management Co., Ltd. (6.0%)
Wellington Management Co. LLP (3.6%)
Nippon Life Insurance Co. (3.4%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.4%)
Nikko Asset Management Co., Ltd. (3.2%)
BlackRock Fund Advisors (3.2%)
Daiwa Asset Management Co. Ltd. (2.8%)
The Vanguard Group, Inc. (2.5%)
Norges Bank Investment Management (1.6%)
BlackRock Japan Co., Ltd. (1.5%)
Contact Details Website: http://www.astellas.com Address:
2-5-1 Nihonbashi-Honcho,
Chuo-Ku,
Tokyo,
103-8411,
Japan
Phone:
+81.3.3244.3000
Related Companies
Astellas Pharma, Inc. /5 Legacy Products/
Astellas Pharma, Inc. /Milrila Injection Product/
OSI Pharmaceuticals, LLC
Representative Office of Astellas Pharma Singapore
Astellas Pharma Malaysia Sdn. Bhd.
Astellas Green Supply, Inc.
Xyphos Biosciences, Inc.
Iota Biosciences, Inc.
Astellas Pharma, Inc. /Agensys Research Facilities/
Astellas Pharma, Inc. /16 Long Listed Products/
Astellas Farma Colombia
Astellas Pharma Director Incentive Plan
Quethera Ltd.
PT Astellas Pharma Indonesia
Astellas Pharma ZAO
Astellas Pharma Hong Kong Co., Ltd.
Astellas Pharma India Pvt Ltd.
Astellas Pharma (Thailand) Co., Ltd.
Astellas Pharma Australia Pty Ltd.
Astellas Pharma Singapore Pte Ltd.
Astellas Pharma Tech Co., Ltd.
Astellas Gene Therapies, Inc.
Mitobridge, Inc.
Astellas Pharma China, Inc.
Perseid Therapeutics LLC
GPDC Partnership
Astellas Pharma Philippines, Inc.
Astellas Pharma Co. Ltd.
Astellas Pharma Canada, Inc.
Fujisawa Taiwan Co. Ltd.
Competitors
AstraZeneca PLC
Roche Holding Ltd
Hanmi Pharmaceutical Co., Ltd.
CrystalGenomics Inc.
Antares Pharma, Inc.
Alembic Pharmaceuticals Limited
AbClon, Inc.
Ipsen SA
DexTech Medical AB
Poseida Therapeutics, Inc.
OSE Immunotherapeutics SA
Golden Biotechnology Corp.
MedPacto, Inc.
Bicycle Therapeutics Plc Sponsored ADR
Agenus Inc.
LegoChem Biosciences, Inc.
DongKoo Bio & Pharm Co. Ltd.
Akebia Therapeutics, Inc.
Sophiris Bio Inc.
Cullinan Oncology, Inc.
GlycoMimetics, Inc.
PTC Therapeutics, Inc.
Agios Pharmaceuticals, Inc.
Biophytis SA
ERYTech Pharma SA
Keros Therapeutics, Inc.
Kura Oncology, Inc.
LogicBio Therapeutics, Inc.
Synthetic Biologics, Inc.
Angion Biomedica Corp.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 18 Oct, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
